Compare ASTH & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASTH | GENB |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2015 | N/A |
| Metric | ASTH | GENB |
|---|---|---|
| Price | $37.66 | $13.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $34.86 | $23.20 |
| AVG Volume (30 Days) | 410.9K | ★ 499.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $519,907,752.00 | N/A |
| Revenue This Year | $27.38 | N/A |
| Revenue Next Year | $10.78 | $16.58 |
| P/E Ratio | $132.17 | ★ N/A |
| Revenue Growth | ★ 45.90 | N/A |
| 52 Week Low | $18.08 | $11.00 |
| 52 Week High | $39.93 | $16.75 |
| Indicator | ASTH | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 46.45 |
| Support Level | $36.95 | $11.63 |
| Resistance Level | $39.93 | $13.76 |
| Average True Range (ATR) | 1.48 | 1.25 |
| MACD | -0.44 | -0.23 |
| Stochastic Oscillator | 28.39 | 18.14 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.